FDAnews Drug Daily Bulletin

Pharma Blog Watch

June 16, 2006
A A

SSRIs, Suicide, and Other Treatment (DrugWonks.com)
The risk of suicide related to selective serotonin reuptake inhibitors (SSRIs) has recently developed into a heated and emotion-fraught issue. In his entry, blogger Peter Pitts discusses SSRIs studies, suicide rates, and the various treatments available to people with clinical depression.

The Ketek Crisis Continues (Eye On FDA)
Citing a recent ABC News report about sanofi-aventis' embattled antibiotic Ketek, blogger Mark Senak discusses Sen. Chuck Grassley's criticism of the FDA about the issue, and lambastes the agency's "continued inability to respond with a communications strategy in the face of a crisis and the intrinsic link between the image of the agency and the image of the pharmaceutical industry itself."